Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Data Hub
Contact
Privacy PolicySusan Fischer from Leiden University Medical Center winner of the MICROB-PREDICT social media award
MICROB-PREDICT supports its early career scientists who promote the project on social media with a free EASL Congress ticket sponsored by EASL. This year`s winner of the social media award is Susan Fischer MD | PhD Candidate Gastroenterology and Hepatology at Leiden University Medical Center. Congratulations Susan and thank youyou’re your continued efforts to disseminate MICROB-PREDICT news on social media!
More newsThe Liver Meeting
After two long years, it's time to reconnect with your peers! Come see the who's who of experts at The Liver Meeting this year at the Walter E. Washington Convention Center, in Washington, DC from 04 – 08 November 2022. Find more information here.
More events